Hizentra

DRUG4 trials

Sponsors

University of South Florida, Rochester General Hospital, CSL Behring, University of Alabama at Birmingham

Conditions

Chronic Inflammatory Demyelinating PolyneuropathyCommon Variable ImmunodeficiencyPrimary Immunodeficiency DisordersSecondary Immune Deficiency Disorder

Phase 2

Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig

CompletedNCT03730129

Rochester General HospitalSecondary Immune Deficiency Disorder

Start: 2018-11-05End: 2020-07-03Updated: 2020-08-26

Phase 4

Usage of Spirometry in Managing IgG Therapy in CVID With Airway Disease

RecruitingNCT05193552

University of Alabama at BirminghamCommon Variable Immunodeficiency

Start: 2024-01-15End: 2027-12-01Target: 22Updated: 2026-05-04

Unknown Phase

Evaluation of Efficacy and Tolerability of Hizentra®

University of South FloridaPrimary Immunodeficiency Disorders

Start: 2010-10-31End: 2012-08-31Target: 50Updated: 2012-07-17

Hizentra® in Inflammatory Neuropathies - pHeNIx Study

RecruitingNCT04672733

CSL BehringChronic Inflammatory Demyelinating Polyneuropathy

Start: 2022-06-10End: 2027-12-31Target: 100Updated: 2025-01-07

Related Papers

Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia.

2021-10-155 citations